Compare SOLS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | PRAX |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | SOLS | PRAX |
|---|---|---|
| Price | $75.44 | $305.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $72.75 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.3M | 306.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $5.00 | $6,395.88 |
| P/E Ratio | $54.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.43 | $26.70 |
| 52 Week High | $84.44 | $354.87 |
| Indicator | SOLS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 44.70 |
| Support Level | $70.72 | $290.36 |
| Resistance Level | $83.07 | $322.32 |
| Average True Range (ATR) | 3.29 | 16.80 |
| MACD | -0.94 | -3.69 |
| Stochastic Oscillator | 41.07 | 25.12 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.